---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-23-000119"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:29:33.230159+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Senti Bio partners with Celest for SENTI-301A development in China; up to $156M milestones

## Summary
- Celest to lead clinical development and manufacturing of SENTI-301A in mainland China; first patient expected 1H 2024.
- Senti Bio retains all commercialization rights outside mainland China, Hong Kong, Macau, and Taiwan.
- Senti eligible for up to $156M in milestone payments plus tiered royalties on potential sales.
- SENTI-301A is an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing hepatocellular carcinoma.
- Pilot trial will enroll 9 patients across two dose cohorts to assess safety and efficacy.

## SEC filing metadata
- accession: 0001854270-23-000119
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000119/0001854270-23-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000119/snti-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-23-000119
- JSON: https://secwatch.observer/filing/0001854270-23-000119.json
- Plain text: https://secwatch.observer/filing/0001854270-23-000119.txt

## Key facts
- Material Agreements
  Senti Biosciences, Inc. entered into Collaboration and Option Agreement with Celest Therapeutics (Shanghai) Co. Ltd. (effective 2023-11-06).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Celest Therapeutics (Shanghai) Co. Ltd.
  - Effective: 2023-11-06
  source text: On November 6, 2023, Senti Biosciences, Inc. (the “ Company ”) entered into a Collaboration and Option Agreement (the “ Agreement ”) with Celest Therapeutics (Shanghai) Co. Ltd.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000119/0001854270-23-000119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.